Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Karl Bayer to Amino Acid Sequence

This is a "connection" page, showing publications Karl Bayer has written about Amino Acid Sequence.

 
Connection Strength
 
 
 
0.860
 
  1. Bayer KU, Schulman H. CaM Kinase: Still Inspiring at 40. Neuron. 2019 08 07; 103(3):380-394.
    View in: PubMed
    Score: 0.130
  2. Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017 06 13; 19(11):2231-2243.
    View in: PubMed
    Score: 0.112
  3. Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6.
    View in: PubMed
    Score: 0.094
  4. Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014 Feb 13; 6(3):431-7.
    View in: PubMed
    Score: 0.089
  5. Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245.
    View in: PubMed
    Score: 0.075
  6. Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72.
    View in: PubMed
    Score: 0.074
  7. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82.
    View in: PubMed
    Score: 0.068
  8. Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU. Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell. 2007 Dec; 18(12):5024-33.
    View in: PubMed
    Score: 0.057
  9. Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J. 2002 Jul 15; 21(14):3590-7.
    View in: PubMed
    Score: 0.040
  10. Bayer KU, L?hler J, Schulman H, Harbers K. Developmental expression of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system. Brain Res Mol Brain Res. 1999 Jun 18; 70(1):147-54.
    View in: PubMed
    Score: 0.032
  11. Bayer KU, Harbers K, Schulman H. alphaKAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. EMBO J. 1998 Oct 01; 17(19):5598-605.
    View in: PubMed
    Score: 0.031
  12. Bayer KU, L?hler J, Harbers K. An alternative, nonkinase product of the brain-specifically expressed Ca2+/calmodulin-dependent kinase II alpha isoform gene in skeletal muscle. Mol Cell Biol. 1996 Jan; 16(1):29-36.
    View in: PubMed
    Score: 0.025
  13. Thein S, Tao-Cheng JH, Li Y, Bayer KU, Reese TS, Dosemeci A. CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS One. 2014; 9(3):e91312.
    View in: PubMed
    Score: 0.022
  14. Nori A, Lin PJ, Cassetti A, Villa A, Bayer KU, Volpe P. Targeting of alpha-kinase-anchoring protein (alpha KAP) to sarcoplasmic reticulum and nuclei of skeletal muscle. Biochem J. 2003 Mar 15; 370(Pt 3):873-80.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)